In addition to the neuroantigen-specific CD8+ Treg cells, it was shown that glatiramer, an FDA-approved first line medication for MS and a peptide mimicking myelin basic protein51, induced HLA-E-restricted CD8+ Treg cells in humans52. Here, CD8A is linked to myeloid sarcoma.